Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Metafora Biosystems is a healthtech company focused on single-cell metabolism profiling, with its first diagnostic test, METAglut1™, now reimbursed in France for early diagnosis of Glut1 deficiency syndrome—a rare neurometabolic disorder. The test offers high specificity and sensitivity, enabling rapid diagnosis via a blood test. The company is also developing assays for cancer and immune cell metabolic fitness, aiming to improve both diagnostics and cell therapy manufacturing. Metafora has received multiple innovation grants and is a laureate of the European Innovation Council Accelerator program. [1][3][5]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on METAFORA biosciences.